Fennec Pharmaceuticals reported ASHA-defined hearing loss in 24.0% of patients in its Japan study, below the prespecified 56.4% historical benchmark, with P=0.001. The result met the primary endpoint and showed no evidence that PEDMARK interfered with cisplatin’s antitumor activity, supporting the company’s Japan registration effort.

Key Highlights

  • PEDMARK produced objective tumor responses in 23 of 24 evaluable patients, or 95.8%.
  • The study found no higher-grade hearing loss under Brock grading.
  • Fennec Pharmaceuticals is pursuing registration in Japan while exploring partnering or licensing opportunities for PEDMARK.

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biotechnology company. On September 17, 2026, the company reported ASHA-defined hearing loss in 24.0% of patients in its Japan study, compared with a prespecified historical benchmark of 56.4% and P=0.001. The primary endpoint was met, with no evidence of interference with cisplatin antitumor activity.

Japan Study Shows Hearing Protection

The primary efficacy population included 25 patients, with 19 remaining free of ASHA-defined hearing loss. That represented 76.0% of the group. The study also found no higher-grade hearing loss under Brock grading. Prospective pharmacokinetic analyses gave mechanistic support to delayed PEDMARK administration after cisplatin, according to the company. The company said it is pursuing registration in Japan and exploring partnering or licensing opportunities for the therapy.

Antitumor Activity Accompanied Hearing Results

Objective tumor responses occurred in 23 of 24 evaluable patients, equal to 95.8%. The company said those findings provided clinical context for delayed PEDMARK administration after cisplatin. Fennec described the results as a significant reduction in hearing loss against the prespecified benchmark. The company said the findings added independent evidence supporting delayed PEDMARK administration.